Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
- 1 May 1997
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 15 (5) , 1965-1973
- https://doi.org/10.1200/jco.1997.15.5.1965
Abstract
PURPOSETo determine the maximum-tolerable dose (MTD) of paclitaxel in a phase I dose-escalation study when combined with cisplatin in patients with advanced ovarian cancer receiving filgrastim for ...Keywords
This publication has 0 references indexed in Scilit: